-
Something wrong with this record ?
Inhibition of soluble epoxide hydrolase counteracts the development of renal dysfunction and progression of congestive heart failure in Ren-2 transgenic hypertensive rats with aorto-caval fistula
L. Červenka, V. Melenovský, Z. Husková, P. Škaroupková, A. Nishiyama, J. Sadowski,
Language English Country Australia
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
NT14050
MZ0
CEP Register
NT14012
MZ0
CEP Register
Digital library NLK
Full text - Article
Full text - Article
Source
Source
NLK
Medline Complete (EBSCOhost)
from 1998-01-01 to 1 year ago
- MeSH
- Angiotensin I metabolism MeSH
- Angiotensin II metabolism MeSH
- Aorta MeSH
- Time Factors MeSH
- Epoxide Hydrolases antagonists & inhibitors chemistry MeSH
- Hemodynamics drug effects MeSH
- Angiotensin-Converting Enzyme Inhibitors pharmacology therapeutic use MeSH
- Enzyme Inhibitors pharmacology therapeutic use MeSH
- Blood Pressure drug effects MeSH
- Rats MeSH
- Fatty Acids, Monounsaturated metabolism MeSH
- Kidney drug effects physiopathology MeSH
- Peptide Fragments metabolism MeSH
- Fistula complications MeSH
- Rats, Transgenic MeSH
- Disease Progression * MeSH
- Renin-Angiotensin System drug effects MeSH
- Renin genetics MeSH
- Solubility MeSH
- Heart Rate drug effects MeSH
- Heart Failure drug therapy etiology physiopathology MeSH
- Cytochrome P-450 Enzyme System metabolism MeSH
- Vena Cava, Inferior MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
The detailed mechanisms determining the course of congestive heart failure (CHF) in hypertensive subjects with associated renal dysfunction remain unclear. In Ren-2 transgenic rats (TGR), a model of angiotensin II (ANG II)-dependent hypertension, CHF was induced by volume overload achieved by creation of the aorto-caval fistula (ACF). In these rats we investigated the putative pathophysiological contribution of epoxyeicosatrienoic acids (EETs) and compared it with the role of the renin-angiotensin system (RAS). We found that untreated ACF TGR exhibited marked intrarenal and myocardial deficiency of EETs and impairment of renal function. Chronic treatment of these rats with cis-4-[4-(3-adamantan-1-yl-ureido)cyclohexyloxy]benzoic acid (c-AUCB, 3 mg/L in drinking water), an inhibitor of soluble epoxide hydrolase (sEH) which normally degrades EETs, increased intrarenal and myocardial EETs, markedly improved survival rate, and increased renal blood flow, glomerular filtration rate and fractional sodium excretion, without altering RAS activity. Chronic angiotensin-converting enzyme inhibition (ACEi) with trandolapril, (6 mg/L in drinking water) improved survival rate even more, and also inhibited the development of renal dysfunction; these beneficial actions were associated with significant suppression of the vasoconstrictor/sodium retaining axis and further activation of the vasodilatory/natriuretic axis of the systemic and intrarenal RAS, without modifying tissue availability of biologically active fatty acid epoxides. In conclusion, these findings strongly suggest that chronic sEH inhibition and chronic treatment with ACEi, each of them altering a different vasoactive system, delay or even prevent the onset of decompensation of CHF in ACF TGR, probably by preventing the development of renal dysfunction.
Department of Cardiology Institute for Clinical and Experimental Medicine Prague Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16010203
- 003
- CZ-PrNML
- 005
- 20191108133917.0
- 007
- ta
- 008
- 160408s2015 at f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/1440-1681.12419 $2 doi
- 024 7_
- $a 10.1111/1440-1681.12419 $2 doi
- 035 __
- $a (PubMed)25969338
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a at
- 100 1_
- $a Červenka, Luděk, $u Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. Department of Pathophysiology, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic. $d 1967- $7 xx0037105
- 245 10
- $a Inhibition of soluble epoxide hydrolase counteracts the development of renal dysfunction and progression of congestive heart failure in Ren-2 transgenic hypertensive rats with aorto-caval fistula / $c L. Červenka, V. Melenovský, Z. Husková, P. Škaroupková, A. Nishiyama, J. Sadowski,
- 520 9_
- $a The detailed mechanisms determining the course of congestive heart failure (CHF) in hypertensive subjects with associated renal dysfunction remain unclear. In Ren-2 transgenic rats (TGR), a model of angiotensin II (ANG II)-dependent hypertension, CHF was induced by volume overload achieved by creation of the aorto-caval fistula (ACF). In these rats we investigated the putative pathophysiological contribution of epoxyeicosatrienoic acids (EETs) and compared it with the role of the renin-angiotensin system (RAS). We found that untreated ACF TGR exhibited marked intrarenal and myocardial deficiency of EETs and impairment of renal function. Chronic treatment of these rats with cis-4-[4-(3-adamantan-1-yl-ureido)cyclohexyloxy]benzoic acid (c-AUCB, 3 mg/L in drinking water), an inhibitor of soluble epoxide hydrolase (sEH) which normally degrades EETs, increased intrarenal and myocardial EETs, markedly improved survival rate, and increased renal blood flow, glomerular filtration rate and fractional sodium excretion, without altering RAS activity. Chronic angiotensin-converting enzyme inhibition (ACEi) with trandolapril, (6 mg/L in drinking water) improved survival rate even more, and also inhibited the development of renal dysfunction; these beneficial actions were associated with significant suppression of the vasoconstrictor/sodium retaining axis and further activation of the vasodilatory/natriuretic axis of the systemic and intrarenal RAS, without modifying tissue availability of biologically active fatty acid epoxides. In conclusion, these findings strongly suggest that chronic sEH inhibition and chronic treatment with ACEi, each of them altering a different vasoactive system, delay or even prevent the onset of decompensation of CHF in ACF TGR, probably by preventing the development of renal dysfunction.
- 650 _2
- $a angiotensin I $x metabolismus $7 D000803
- 650 _2
- $a angiotensin II $x metabolismus $7 D000804
- 650 _2
- $a inhibitory ACE $x farmakologie $x terapeutické užití $7 D000806
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a aorta $7 D001011
- 650 _2
- $a krevní tlak $x účinky léků $7 D001794
- 650 _2
- $a systém (enzymů) cytochromů P-450 $x metabolismus $7 D003577
- 650 12
- $a progrese nemoci $7 D018450
- 650 _2
- $a inhibitory enzymů $x farmakologie $x terapeutické užití $7 D004791
- 650 _2
- $a epoxid hydrolasy $x antagonisté a inhibitory $x chemie $7 D004851
- 650 _2
- $a kyseliny mastné mononenasycené $x metabolismus $7 D005229
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a píštěle $x komplikace $7 D005402
- 650 _2
- $a srdeční selhání $x farmakoterapie $x etiologie $x patofyziologie $7 D006333
- 650 _2
- $a srdeční frekvence $x účinky léků $7 D006339
- 650 _2
- $a hemodynamika $x účinky léků $7 D006439
- 650 _2
- $a ledviny $x účinky léků $x patofyziologie $7 D007668
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a peptidové fragmenty $x metabolismus $7 D010446
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani transgenní $7 D055647
- 650 _2
- $a renin $x genetika $7 D012083
- 650 _2
- $a renin-angiotensin systém $x účinky léků $7 D012084
- 650 _2
- $a rozpustnost $7 D012995
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a vena cava inferior $7 D014682
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Melenovský, Vojtěch $u Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. $7 xx0160847
- 700 1_
- $a Husková, Zuzana, $u Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. $d 1978- $7 xx0074206
- 700 1_
- $a Škaroupková, Petra $u Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. $7 xx0117683
- 700 1_
- $a Nishiyama, Akira $u Department of Pharmacology, Kagawa University, Kagawa, Japan.
- 700 1_
- $a Sadowski, Janusz $u Department of Renal and Body Fluid Physiology, M. Mossakowski Medical Research Centre, Polish Academy of Science, Warsaw, Poland.
- 773 0_
- $w MED00007158 $t Clinical and experimental pharmacology & physiology $x 1440-1681 $g Roč. 42, č. 7 (2015), s. 795-807
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25969338 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160408 $b ABA008
- 991 __
- $a 20191108134149 $b ABA008
- 999 __
- $a ok $b bmc $g 1113632 $s 934571
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 42 $c 7 $d 795-807 $i 1440-1681 $m Clinical and experimental pharmacology & physiology $n Clin Exp Pharmacol Physiol $x MED00007158
- GRA __
- $a NT14050 $p MZ0
- GRA __
- $a NT14012 $p MZ0
- LZP __
- $a Pubmed-20160408